Trials / Completed
CompletedNCT00652457
Study of Memantine to Treat Huntington's Disease
A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease"
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Jody Corey-Bloom, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).
Detailed description
Results of several published clinical trials suggest that memantine has a beneficial effect in dementing conditions, such as Alzheimer's disease; however, the effects of memantine on cognitive and behavioral function in HD are unknown. Our hypotheses are that HD patients who are administered memantine will show improved performance on psychometric tests of memory and executive functions in addition to behavior and that patients treated with memantine will show more improvement after six months than after three months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine | 10 mg BID x 3 months |
Timeline
- Start date
- 2004-11-23
- Primary completion
- 2009-10-28
- Completion
- 2009-10-28
- First posted
- 2008-04-03
- Last updated
- 2021-01-05
- Results posted
- 2021-01-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00652457. Inclusion in this directory is not an endorsement.